Valuation: GlaxoSmithKline plc

Market Cap 77.4B 104B 90.57B 84.3B 146B 9,945B 148B 994B 390B 4,951B 391B 383B 16,602B P/E 2026 *
12.7x
P/E 2027 * 11.3x
Enterprise Value 95.16B 128B 111B 104B 180B 12,228B 182B 1,222B 479B 6,088B 481B 471B 20,413B EV / Sales 2026 *
2.8x
EV / Sales 2027 * 2.58x
Free-Float
92.75%
Yield 2026 *
3.6%
Yield 2027 * 3.79%
Manager TitleAgeSince
Chief Executive Officer - 31/12/2025
Director of Finance/CFO 64 30/04/2023
Chief Tech/Sci/R&D Officer - 30/11/2021
Director TitleAgeSince
Director/Board Member - 05/05/2026
Director/Board Member 64 31/12/2017
Chairman 68 31/08/2019
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-0.40% - - 104B
-0.53%-3.95%+50.70%+153.56% 1,024B
+0.21%-2.68%+53.20%+51.79% 618B
-2.51%-3.25%+28.54%+68.94% 443B
+0.06%-0.42%+37.53%+30.67% 349B
-0.69%-0.30%+13.76%+12.83% 264B
-7.37%-4.40%-0.74%-44.28% 209B
-0.64%+2.43%+29.74%+65.93% 208B
-0.82%+0.70%+15.05%+72.05% 162B
+0.40%+1.92%+6.47%-29.77% 143B
Average -1.19%-1.21%+26.03%+42.41% 379.88B
Weighted average by Cap. -0.97%-2.02%+36.14%+71.90%

Financials

2026 *2027 *
Net sales 33.99B 45.75B 39.77B 37.02B 64.18B 4,368B 65.18B 436B 171B 2,174B 172B 168B 7,291B 35.62B 47.95B 41.68B 38.79B 67.26B 4,577B 68.3B 457B 179B 2,279B 180B 176B 7,641B
Net income 6.17B 8.31B 7.22B 6.72B 11.65B 793B 11.83B 79.23B 31.09B 395B 31.2B 30.51B 1,324B 6.96B 9.37B 8.14B 7.58B 13.14B 894B 13.34B 89.33B 35.06B 445B 35.18B 34.4B 1,493B
Net Debt 17.76B 23.91B 20.79B 19.35B 33.55B 2,283B 34.07B 228B 89.51B 1,136B 89.81B 87.84B 3,811B 14.52B 19.55B 16.99B 15.82B 27.42B 1,866B 27.85B 186B 73.16B 929B 73.41B 71.79B 3,115B
Logo GlaxoSmithKline plc
GSK plc is the world's No. 2 pharmaceutical group. Net sales break down by family of products as follows: - pharmaceutical products (41.3%): intended mainly for HIV infection (57% of net sales), immune system disorders and respiratory diseases (28.3%), and cancer (14.7%); - OTC and parapharmaceutical medicine (30.7%); - vaccines (28%). Net sales are distributed geographically as follows: the United Kingdom (2.1%), Europe (21%), the United States (51.6%), and other (25.3%).
Employees
-
Trader
Investor
Global
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
22
Last Close Price
19.32GBP
Average target price
21.42GBP
Spread / Average Target
+10.90%

Quarterly revenue - Rate of surprise